Clonal driver neoantigen loss under <i>EGFR</i> TKI and immune selection pressures
Nature, Published online: 19 February 2025; doi:10.1038/s41586-025-08586-yWe show the evolution of a case of EGFR mutant lung cancer treated with a combination of erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine targeting somatic mutations, including EGFR exon 19 deletion.
Nature, Published online: 19 February 2025; doi:10.1038/s41586-025-08586-yWe show the evolution of a case of EGFR mutant lung cancer treated with a combination of erlotinib, osimertinib, radiotherapy and a personalized neopeptide vaccine targeting somatic mutations, including EGFR exon 19 deletion.
